SteriPlas treatment for Acne Vulgaris
We are excited to announce the recent publication, “Cold atmospheric plasma (CAP) as a promising therapeutic option for mild to moderate acne vulgaris” which features our Adtec SteriPlas cold plasma for the treatment of acne.
The paper created by Dr Mariachiara Arisi from the Department of Dermatology at the University of Brescia, Italy demonstrates the antibacterial efficacy of our patented cold plasma for the treatment of acne vulgaris patients. It indicates the significant reduction of acne skin lesions in treated patients who were previously unsuccessful treated with topical drugs. Unlike topical drugs, the Adtec SteriPlas demonstrated a safe, effective, and well-tolerated treatment option with no side effects for the treatment of acne patients.
No adverse effects or skin reactions were reported either during the treatment nor at 3-months follow-up. Treatment was completely painless and well tolerated. Patients did not report itching or burning sensation during plasma application and in the following days.
The full paper can be found here: https://www.sciencedirect.com/science/article/pii/S2212816620300172
Leading cold plasma medical device
The Adtec SteriPlas is the leading cold plasma medical device used to manage the infection in chronic wounds, surgical site infections and to treat dermatological conditions such as acne and actinic keratoses.
With our wide clinical trials and publications bibliography, we are proud to state its strong antibacterial efficacy regardless of the type of bacteria or its resistance profile. There have been no side effects reported with the use of our medical device since it is safe, painless to touch and an effective method of treating patients from conventional therapies.
Adtec Healthcare exhibiting at two leading wound conferences this year
Adtec Healthcare looks forward to exhibit at the European Wound Management Association (EWMA) conference and The Malvern Diabetic Foot Conference in May 2020. As the two conferences will be running on the same dates (13th-15th May ’20), we will have teams exhibiting at both conferences so we can meet with you at whichever conference you attend.
We will have our medical device live on display at both exhibitions and look forward to inviting you to our booth to give a demonstration on its ease of use to achieve remarkable results.
#EWMA #EWMA2020 #MalvernDFU #Malvern2020 #wound #wundkongress #coldplasma #kaltesplasma #gasplasma #plasma #exhibition #woundcare #surgicalsiteinfection #preventSSI #SSIprevention
Randomised Controlled Clinical Trials of Adtec SteriPlas/MicroPlaSter Plasma Treatment of Wounds and Dermatological conditions over a 14 year period.
Adtec Healthcare’s plasma technology has been tested in 7 randomised controlled clinical trials with proven clinical efficacy and safety. The first participant in an RCT with our plasma technology was on 24th October 2005 - This was also the first RCT worldwide to investigate the clinical efficacy of cold plasma. We continue to be actively involved in RCTs and clinical studies with SteriPlas to produce strong clinical evidence.
The results of these trials include wound size reduction, bigger reduction of bacterial load compared to antibiotics, treatment of AK lesions and reduction of pain with no adverse events reported.
1. ACTICAP - A prospective, randomised, monocentric, rater blinded study evaluating the change of the cutaneous microbiome in correlation to the efficacy of cold atmospheric plasma treatment in comparison to diclofenac 3% in 2.5% hyaluronic acid (Solaraze 3% Gel®) in patients with actinic keratoses
University Hospital Essen, Germany
Status – Trial completed 2019 and publication planned 2020
2. Prospective, Randomised and Placebo Controlled Clinical Trial (RCT) for the validation of treatment of chronic wounds with cold atmospheric plasma (CAP)
University Hospital Essen, Germany
Status – Trial completed 2018 and publication planned 2020
3. A randomised controlled trial to evaluate the efficacy of non-thermal gas plasma (NTGP) on sub-clinical wound infection (biofilm) in patients with diabetic foot ulcers compared to those treated with standard of care dressings
Salford Royal Foundation Trust, UK
Leeds TeachingHospital, UK
Status – Trial ongoing
4. Low temperature argon plasma for in vivo sterilization of chronic wounds
Klinikum Schwabing, Germany
University Hospital Regensburg Germany
Status – Trial completed 2013 and published
Successful and Safe Use of 2 Min Cold Atmospheric Argon Plasma in Chronic Wounds: Results of A Randomized Controlled Trial. Isbary ,British Journal of Dermatology, 2012.
A first prospective randomized controlled trial to decrease bacterial load using cold atmospheric argon plasma on chronic wounds in patients, Isbary ,British Journal of Dermatology, 2010
5. Randomised placebo-controlled human pilot study of cold atmospheric argon plasma on skin graft donor sites
University Hospital Regensburg Germany
Status – Trial completed and published
Randomized placebo-controlled human pilot study of cold atmospheric argon plasma on skin graft donor sites. Heinlin Wound Repair Reg 2013
6. Randomised placebo-controlled clinical trial showed cold atmospheric
argon plasma in herpes zoster
Klinikum Schwabing, Germany
University Hospital Regensburg Germany
Status – Trial completed and published
Randomized placebo-controlled clinical trial showed cold atmospheric argon `plasma relieved acute pain and accelerated healing in herpes zoster, Isbary , Clinical Plasma Medicine,2014,
7. A randomised two-sided placebo-controlled study on the efficacy and safety of atmospheric non-thermal argon plasma for pruritus
Klinikum Schwabing, Germany
University Hospital Regensburg Germany
Status – Trial completed and published
A randomized two-sided placebo-controlled study on the efficacy and safety of atmospheric non-thermal argon plasma for pruritus, Heinlin, J Eur Acad Dermatol Venereol. 2013.
Adtec Plasma in CSP Renewable Energy Project
Adtec Europe Ltd is sponsoring two post-graduate students to do research in new potential applications for plasma in collaboration with Cranfield University.
The focus of this research is to understand the utilisation of plasma-assisted surface conditioning of low-iron glass solar reflecting mirrors for concentrating solar thermal power applications. The research project is supervised by leading experts in this field Professor Chris Sansom and Dr Peter King of Cranfield University and Dr Adam Bennett of Cranfield Plasma Solutions.
CSP plants generate electricity by concentrating sun light with large arrays of mirrors which are usually located in desert regions. Consequently, the mirrors get covered in sand and dust, and require cleaning with brushes and water on a regular basis. Currently much water is used to clean the mirrors, a precious resource in arid terrains. The aim of this project is to investigate the characteristics of a novel atmospheric pressure plasma system used to condition CSP concentrating mirrors which will be capable of reducing the amount of water used in the cleaning process.
The Global Concentrating Solar Power (CSP) market was valued at over $3 Billion US in 2016 and is anticipated to grow by 13% by 2025. There is also a compelling business desire to undertake this project. The development of a novel atmospheric pressure plasma system will be a significant game changer in the CSP market. Such a disruptive technology is anticipated to yield significant commercial benefits.
#CSP #concentratingsolarpower #solarpower #solar #solarenergy #renewableenergy #greenenergy #energy #cleanenergy #sustainableenergy #sustainablepower #sustainableenvironment #plasma #gasplasma #coldplasma #kaltesplasma #airplasma
EWMA
We had a great time exhibiting at the EWMA 2019 conference. We would like to congratulate Maurice Moelleken, Dr Heinrich Rotering and Dr Michael Pierides for their brilliant presentations during the conference. Their data showed the strong benefits of using the Adtec SteriPlas on chronic wounds and surgical site infections, offering an alternative to standard treatment therapies that bacteria may pose a resistance to.
The Adtec SteriPlas has proven antibacterial efficacy backed by a wide clinical bibliography and no side effects reported making it safe, painless and effective for the treatment of infected wounds stalled by bacteria.
For more information send us an email to info@adtec.eu.com
#EWMA #EWMA2019 #antimicrobialresistance #medicaldevice
#gasplasma #coldplasma #kaltesplasma
Surgical site infections treated with the Adtec SteriPlas
Surgical site infections (SSIs) are still a severe complication after cardiac surgery with a mortality estimated range of up to 40% of cases. These post-operative wounds are generally associated with longer hospital stay and the delayed or inadequate therapeutic measures can lead to avoidable hospital costs for the healthcare system. The significant cost burden on the hospital for a single SSI case is €36,000. 1
It has already been shown that the Adtec SteriPlas is effective due to its increased penetration depth in SSIs to defeat bacteria even under a layer of biofilm independently to their resistance profile. This includes multi-resistant bacteria that have shown little or no response to antibiotics previously. In combination with advanced negative pressure wound treatment (aNPWT), the Adtec SteriPlas has been praised as a “tissue saving approach” offering patients a favourable treatment method for these complicated and chronic wounds compared to conventional treatment therapies. 2
Studies conducted using the Adtec SteriPlas have shown a significant decrease in the mortality rate coupled with accelerated healing. Patients with infected drivelines such as those with left ventricular assist devices have healed in as quick as 1 week, and patients with sternal SSIs have healed in as quick as 6 days. 2,3
Both patients and doctors have praised the Adtec SteriPlas for its exceptional ability at delivering promising results leading to healing.
Be sure to contact us for more information and to see how our medical device may benefit your patients.
- H. Rotering, Cold atmospheric plasma – New options for infection control in wound management, EWMA 2016.
- H. Rotering, Cold atmospheric plasma and advanced Negative Pressure Wound Treatment – First results of a tissue saving approach for deep surgical site infections, EACTS 2018.
- H. Rotering, Das infizierte Implantat, Komplexe Wundbehandlung – Kaltes atmospherisches Plasma und advanced NPWT in der Herzchirurgie, Chirurgie 2019.
Adtec receives second place award in the ‘Most Innovative Product’ Category in Journal of Wound Care awards
We are delighted to be awarded second place in the ‘Most Innovative Product:’ category at the Journal of Wound Care/ World Union of Wound Healing Societies awards. The results were announced at the awards ceremony on Tuesday September 27th during the WUWHS congress in Florence.
Adtec introduces the plasma product portfolio designed and manufactured in the UK by Adtec Europe Limited
Plasma processing is a material processing technology that is utilized to modify the chemical and physical properties of a surface. Plasma processing is most often in vacuum plasma chambers widely used in the semiconductor and display industries to meet the critical engineering requirements of high-tech industries.
Adtec Healthcare congratulates the R&D Manager Takuya Urayama on receipt of the second place award for Most Innovative Product at JWC Awards 2017.
Takuya is design leader for the Adtec SteriPlas gas plasma device. He also leads the team for development of Adtec microwave gas plasma devices in other applications such as sanitisation of hard to clean areas in food factories and surface treatment.